- Report
- January 2021
- 221 Pages
Global
From €3224EUR$3,600USD£2,749GBP
- Report
- December 2024
- 123 Pages
China
From €1612EUR$1,800USD£1,374GBP
- Report
- December 2024
- 267 Pages
China
From €3583EUR$4,000USD£3,054GBP
- Report
- December 2024
- 94 Pages
China
From €1612EUR$1,800USD£1,374GBP
- Report
- August 2024
- 229 Pages
China
From €3583EUR$4,000USD£3,054GBP
- Report
- June 2024
- 170 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- December 2023
- 272 Pages
Global
€4474EUR$4,995USD£3,814GBP
- Report
- January 2025
- 113 Pages
Global
From €3500EUR$4,186USD£3,088GBP
From €116EUR$129USD£98GBP
- Report
- August 2024
- 93 Pages
China
From €1612EUR$1,800USD£1,374GBP
- Report
- March 2024
- 132 Pages
Global
From €851EUR$950USD£725GBP
- Book
- October 2019
- 720 Pages
The Macrolide Antibiotic market is a segment of the Infectious Diseases Drugs market. Macrolides are a class of antibiotics used to treat a wide range of bacterial infections, including respiratory tract infections, skin infections, and sexually transmitted diseases. Macrolides are generally well-tolerated and have fewer side effects than other antibiotics. They are also effective against drug-resistant bacteria, making them an important tool in the fight against antibiotic resistance. Macrolides are available in both oral and intravenous formulations, and are often used in combination with other antibiotics.
The Macrolide Antibiotic market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, and Novartis. Show Less Read more
